Literature DB >> 26101573

Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.

William T McElroy1, Zheng Tan1, Ginny Ho1, Sunil Paliwal1, Guoqing Li1, W Michael Seganish1, Deen Tulshian1, James Tata1, Thierry O Fischmann1, Christopher Sondey1, Hong Bian1, Loretta Bober1, James Jackson1, Charles G Garlisi1, Kristine Devito1, James Fossetta1, Daniel Lundell1, Xiaoda Niu1.   

Abstract

IRAK4 is a critical upstream kinase in the IL-1R/TLR signaling pathway. Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders. A screening campaign identified a pyrazole class of IRAK4 inhibitors that were determined by X-ray crystallography to exhibit an unusual binding mode. SAR efforts focused on the identification of a potent and selective inhibitor with good aqueous solubility and rodent pharmacokinetics. Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogues generally having good rodent oral exposure but poor solubility. N-Alkyl piperidines exhibited excellent solubility and reduced exposure. Pyrazoles possessing N-1 pyridine and fluorophenyl substituents were among the most active. Piperazine 32 was a potent enzyme inhibitor with good cellular activity. Compound 32 reduced the in vivo production of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.

Entities:  

Keywords:  Interleukin-1 receptor-associated kinase 4; SAR; drug discovery; inflammation; structure-based drug design

Year:  2015        PMID: 26101573      PMCID: PMC4468401          DOI: 10.1021/acsmedchemlett.5b00106

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  20 in total

Review 1.  The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?

Authors:  Timothy J Ritchie; Simon J F Macdonald
Journal:  Drug Discov Today       Date:  2009-09-01       Impact factor: 7.851

2.  Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.

Authors:  H He; K A Lyons; X Shen; Z Yao; K Bleasby; G Chan; M Hafey; X Li; S Xu; G M Salituro; L H Cohen; W Tang
Journal:  Xenobiotica       Date:  2009-09       Impact factor: 1.908

3.  Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery.

Authors:  W A Korfmacher; K A Cox; K J Ng; J Veals; Y Hsieh; S Wainhaus; L Broske; D Prelusky; A Nomeir; R E White
Journal:  Rapid Commun Mass Spectrom       Date:  2001       Impact factor: 2.419

Review 4.  Inflammation, ageing and chronic disease.

Authors:  Graham Pawelec; David Goldeck; Evelyna Derhovanessian
Journal:  Curr Opin Immunol       Date:  2014-04-22       Impact factor: 7.486

Review 5.  IRAK-4--a shared NF-kappaB activator in innate and acquired immunity.

Authors:  Nobutaka Suzuki; Takashi Saito
Journal:  Trends Immunol       Date:  2006-12       Impact factor: 16.687

Review 6.  Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.

Authors:  Divya Chaudhary; Shaughnessy Robinson; Donna L Romero
Journal:  J Med Chem       Date:  2014-12-05       Impact factor: 7.446

Review 7.  The potential of targeting Toll-like receptor 2 in autoimmune and inflammatory diseases.

Authors:  E M Pålsson-McDermott; L A J O'Neill
Journal:  Ir J Med Sci       Date:  2007-11-15       Impact factor: 1.568

8.  Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.

Authors:  L Nathan Tumey; Diane H Boschelli; Niala Bhagirath; Jaechul Shim; Elizabeth A Murphy; Deborah Goodwin; Eric M Bennett; Mengmeng Wang; Lih-Ling Lin; Barry Press; Marina Shen; Richard K Frisbie; Paul Morgan; Shashi Mohan; Julia Shin; Vikram R Rao
Journal:  Bioorg Med Chem Lett       Date:  2014-03-29       Impact factor: 2.823

Review 9.  Targeting Toll-like receptors with small molecule agents.

Authors:  Xiaohui Wang; Christina Smith; Hang Yin
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

Review 10.  Inflammation and cardiovascular disease mechanisms.

Authors:  Peter Libby
Journal:  Am J Clin Nutr       Date:  2006-02       Impact factor: 7.045

View more
  13 in total

1.  Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4-MyD88 Complex.

Authors:  Balyn W Zaro; Ekaterina V Vinogradova; Daniel C Lazar; Megan M Blewett; Radu M Suciu; Junichiro Takaya; Sean Studer; Juan Carlos de la Torre; Jean-Laurent Casanova; Benjamin F Cravatt; John R Teijaro
Journal:  J Immunol       Date:  2019-03-18       Impact factor: 5.422

2.  Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4).

Authors:  Li Wang; Ryan Ferrao; Qiubai Li; John M Hatcher; Hwan Geun Choi; Sara J Buhrlage; Nathanael S Gray; Hao Wu
Journal:  J Biol Chem       Date:  2019-01-24       Impact factor: 5.157

3.  Crystal structure of human IRAK1.

Authors:  Li Wang; Qi Qiao; Ryan Ferrao; Chen Shen; John M Hatcher; Sara J Buhrlage; Nathanael S Gray; Hao Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-05       Impact factor: 11.205

4.  Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity.

Authors:  Shailesh Dudhgaonkar; Sourabh Ranade; Jignesh Nagar; Siva Subramani; Durga Shiv Prasad; Preethi Karunanithi; Ratika Srivastava; Kamala Venkatesh; Sabariya Selvam; Prasad Krishnamurthy; T Thanga Mariappan; Ajay Saxena; Li Fan; Dawn K Stetsko; Deborah A Holloway; Xin Li; Jun Zhu; Wen-Pin Yang; Stefan Ruepp; Satheesh Nair; Joseph Santella; John Duncia; John Hynes; Kim W McIntyre; Julie A Carman
Journal:  J Immunol       Date:  2016-12-21       Impact factor: 5.422

Review 5.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

Review 6.  Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011-2020): Current Status and Future Prospects.

Authors:  Mohammed I El-Gamal; Seyed-Omar Zaraei; Moustafa M Madkour; Hanan S Anbar
Journal:  Molecules       Date:  2022-01-05       Impact factor: 4.411

7.  Rapid Evaluation of Small Molecule Cellular Target Engagement with a Luminescent Thermal Shift Assay.

Authors:  Jonathan D Mortison; Ivan Cornella-Taracido; Gireedhar Venkatchalam; Anthony W Partridge; Nirodhini Siriwardana; Simon M Bushell
Journal:  ACS Med Chem Lett       Date:  2021-07-12       Impact factor: 4.632

8.  Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors.

Authors:  Yan Chen; Rajinder Singh; Nan Lin; Vanessa Taylor; Esteban S Masuda; Donald G Payan
Journal:  ACS Med Chem Lett       Date:  2022-04-04       Impact factor: 4.632

9.  Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins.

Authors:  Sirish K Ippagunta; Julie A Pollock; Naina Sharma; Wenwei Lin; Taosheng Chen; Kazuki Tawaratsumida; Anthony A High; Jaeki Min; Yizhe Chen; R Kiplin Guy; Vanessa Redecke; John A Katzenellenbogen; Hans Häcker
Journal:  Sci Signal       Date:  2018-08-14       Impact factor: 8.192

10.  Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.

Authors:  Priscilla N Kelly; Donna L Romero; Yibin Yang; Arthur L Shaffer; Divya Chaudhary; Shaughnessy Robinson; Wenyan Miao; Lixin Rui; William F Westlin; Rosana Kapeller; Louis M Staudt
Journal:  J Exp Med       Date:  2015-11-30       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.